6 assets in Refractory Hematologic Cancer

Therapeutic assets addressing Refractory Hematologic Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Gm-Csf Refractory Hematologic Cancer	The First Affiliated Hospital of Xiamen University	P2	CCC (53)
Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,461-Alanine,462-Alanine,556-Glycine,581-Cysteine,593-Tryptophan), Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 Vh-Ch1 Fragment) Fusion Protein With Peptide (Synthetic 10-Amino Acid Linker) Fusion Protein With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Heavy Chain Vl(.Lambda.)-Ch1-Ch2-Ch3), (222->219''')-Disulfide With Immunoglobulin Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine)) And (447->232'')-Disulfide With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Light Chain Vh-Cl(.Kappa.)), (453->228'), (456->231'), (581->351')-Tris(Disulfide) With Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,236-Alanine,237-Alanine,331-Glycine,351-Cysteine,368-Serine,370-Alanine,409-Valine) Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Gamma.1-Chain) Disulfide With Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine) Refractory Hematologic Cancer	The First Affiliated Hospital of Xiamen University	P2	CCC (53)
Lenalidomide Refractory Hematologic Cancer	The First Affiliated Hospital of Xiamen University	P2	CCC (53)
Emavusertib Refractory Hematologic Cancer	Curis, Inc.	P1/2	CCC (48)
Ibrutinib Refractory Hematologic Cancer	Curis, Inc.	P1/2	CCC (48)
cd19-ucart Refractory Hematologic Cancer	iCell Gene Therapeutics	P1	CC (43)